The Federated Health Intelligence Network needs an opinionated foundation. The first 100 members are not buyers. They are the people whose names appear on what the network becomes — signal-by-signal, verdict-by-verdict — and whose judgment AimwellBio is built to be accountable to.
“What changes when you’re inside the cohort that shaped this network — before the network is what everyone else discovers?”
Membership is mutual. The Founding 100 receive privileges. AimwellBio commits, in writing, to operating under principles the cohort can hold the company to. These are not marketing claims. They are the terms of the network.
Read across every FHIN tier — Observer, Contributor, Researcher, Institutional — without gating. Every signal, every adversarial validation thread.
Every new capability ships to the cohort 90 days before general release. Your feedback is in the room where decisions are made — not after.
September 2026 · charter-only working session. Signal methodology, cross-cohort introductions, year-ahead roadmap. One seat per founder.
Whatever AimwellBio raises pricing to as it scales, your founding rate is locked for life. Documented in the Charter, enforceable in writing.
Verifiable credential for LinkedIn, email signature, publications. Externally carrier-able — identity belongs to you, not us.
One-time admission. Lifetime cohort membership. Founding rate on every recurring tier AimwellBio offers from this day forward. The 101st founder pays a different price for a different product.
The cohort fills in its own time. If you want to be on the list for the next cohort (whenever that is, on whatever terms it carries), or if you want to receive the cohort’s published artifacts — signal methodology papers, symposium notes, the annual Charter update — subscribe below. No sales follow-up. Just the work.
What position will you hold in the validation layer if the cohort that defined it is named by 2026-09-01?
Want to read the charter before joining? See /founding-charter →
Plus: founding members get founding-rate pricing locked for life + acknowledgments-page citation on the methodology paper + personal onboarding with John Morgan.
Hand us anything your team is about to use. We return a source-risk review with every citation traced. No sales call. No follow-up sequence. The review itself is the conversation.
Teams searched documents, reviewed guidance updates, followed trial movement, tracked competitors, and built internal briefs by hand. Slow but auditable. Every claim had a paper trail.
Speed. The same brief that took a week now takes minutes. The trade-off: unsupported claims, stale guidance, missing context, and incomplete summaries can now move into serious decisions before anyone challenges them.
AimwellBio is the verification layer that sits between AI-generated intelligence and the decision someone signs their name to. Source-trace, adversarial review, confidence labels, institutional memory.
Seven ways unsupported scientific intelligence can enter regulatory, clinical, board, and investor workflows. Open to credentialed professionals. No sales sequence, no list-trading.